BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31912799)

  • 21. Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study.
    Huang C; Gu X; Zeng X; Chen B; Yu W; Chen M
    BMC Cancer; 2021 Jan; 21(1):30. PubMed ID: 33413175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
    Shitara K; Yonesaka K; Denda T; Yamazaki K; Moriwaki T; Tsuda M; Takano T; Okuda H; Nishina T; Sakai K; Nishio K; Tokunaga S; Yamanaka T; Boku N; Hyodo I; Muro K
    Cancer Sci; 2016 Dec; 107(12):1843-1850. PubMed ID: 27712015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
    Hofmann FO; Heinemann V; D'Anastasi M; Gesenhues AB; Hesse N; von Weikersthal LF; Decker T; Kiani A; Moehler M; Kaiser F; Heintges T; Kahl C; Kullmann F; Scheithauer W; Link H; Modest DP; Stintzing S; Holch JW
    Eur Radiol; 2023 Feb; 33(2):1174-1184. PubMed ID: 35976398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
    Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of
    Stintzing S; van Oostrum I; Pescott CP; Ronga P; Heeg B; Heinemann V
    J Med Econ; 2020 May; 23(5):448-455. PubMed ID: 31903807
    [No Abstract]   [Full Text] [Related]  

  • 26. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
    Peeters M; Oliner KS; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; He P; Yu H; Koukakis R; Terwey JH; Jung AS; Sidhu R; Patterson SD
    Clin Cancer Res; 2015 Dec; 21(24):5469-79. PubMed ID: 26341920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306.
    Froelich MF; Petersen EL; Heinemann V; Nörenberg D; Hesse N; Gesenhues AB; Modest DP; Sommer WH; Hofmann FO; Stintzing S; Holch JW
    Clin Colorectal Cancer; 2020 Dec; 19(4):291-300.e5. PubMed ID: 32917529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
    Liu L; Erickson NT; Ricard I; von Weikersthal LF; Lerch MM; Decker T; Kiani A; Kaiser F; Heintges T; Kahl C; Kullmann F; Scheithauer W; Link H; Höffkes HG; Moehler M; Gesenhues AB; Theurich S; Michl M; Modest DP; Algül H; Stintzing S; Heinemann V; Holch JW
    Int J Cancer; 2022 Jan; 150(1):112-123. PubMed ID: 34431518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G).
    Izawa N; Shitara K; Yonesaka K; Yamanaka T; Yoshino T; Sunakawa Y; Masuishi T; Denda T; Yamazaki K; Moriwaki T; Okuda H; Kondoh C; Nishina T; Makiyama A; Baba H; Yamaguchi H; Nakamura M; Hyodo I; Muro K; Nakajima TE
    Target Oncol; 2020 Oct; 15(5):623-633. PubMed ID: 32960408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
    Obermannová R; Van Cutsem E; Yoshino T; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia Alfonso P; Portnoy D; Cohn A; Yamazaki K; Clingan P; Lonardi S; Kim TW; Yang L; Nasroulah F; Tabernero J
    Ann Oncol; 2016 Nov; 27(11):2082-2090. PubMed ID: 27573561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
    Ito T; Takashima A; Yamazaki K; Yukami H; Uetake H; Tsuda M; Suto T; Moriwaki T; Sugimoto N; Ojima H; Takii Y; Yasui H; Esaki T; Tsuji A; Goto M; Saruta M; Otsu S; Shinozaki K; Fujiwara T; Tamura T; Baba E; Shiozawa M; Denda T; Ueno H; Nagashima K; Shimada Y
    Int J Clin Oncol; 2022 Sep; 27(9):1450-1458. PubMed ID: 35861943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
    Fischer LE; Stintzing S; von Weikersthal LF; Modest DP; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Giessen-Jung C; Uhlig J; Peuser B; Denzlinger C; Stahler A; Weiss L; Heinrich K; Held S; Jung A; Kirchner T; Heinemann V
    Br J Cancer; 2022 Sep; 127(5):836-843. PubMed ID: 35637412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness Analysis of First-Line FOLFIRI Combined With Cetuximab or Bevacizumab in Patients With RAS Wild-Type Left-Sided Metastatic Colorectal Cancer.
    Han J; Xiao D; Tan C; Zeng X; Hu H; Zeng S; Jiang Q; She L; Yao L; Li L; Tang L; Ma J; Huang J; Shen L
    Cancer Control; 2020; 27(1):1073274820902271. PubMed ID: 32107929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.
    Köhne CH; Poston G; Folprecht G; Ciardiello F; Ronga P; Beier F; Van Cutsem E
    Eur J Surg Oncol; 2016 Oct; 42(10):1540-7. PubMed ID: 27575968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
    Sastre J; García-Alfonso P; Viéitez JM; Cano MT; Rivera F; Reina-Zoilo JJ; Salud-Salvia A; Quintero G; Robles-Díaz L; Safont MJ; La Casta A; Gil S; Polo E; Asensio-Martínez E; García-Paredes B; López RL; Guillot M; Valladares-Ayerbes M; Aranda E; Díaz-Rubio E;
    ESMO Open; 2021 Apr; 6(2):100062. PubMed ID: 33711671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of
    Stintzing S; Heinrich K; Tougeron D; Modest DP; Schwaner I; Eucker J; Pihusch R; Stauch M; Kaiser F; Kahl C; Karthaus M; Müller C; Burkart C; Reinacher-Schick A; Kasper-Virchow S; Fischer von Weikersthal L; Krammer-Steiner B; Prager GW; Taieb J; Heinemann V
    J Clin Oncol; 2023 Sep; 41(25):4143-4153. PubMed ID: 37352476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.